Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 10/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 9/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 7/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.54 |
| ▸ | CDK9 | P50750 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452842 | 0.79 | TNF (0.56) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL5489472 | 0.79 | BRD4 (0.42) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL9216298 | 0.76 | TNF (0.53) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL10245157 | 0.76 | TNF (0.57) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL102527 | 0.76 | TNF (0.53) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL2943467 | 0.76 | TNF (0.53) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL16531904 | 0.73 | TNF (0.54) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL22159024 | 0.73 | TNF (0.50) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL430605 | 0.73 | TNF (0.50) | TNFDYRK1ADYRK2DYRK1BCDK5 | |
| SCHEMBL22834762 | 0.72 | DYRK1A (0.57) | TNFDYRK1ADYRK2DYRK1BCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-118894823-A | Naphthylamide compound serving as VEGFR inhibitor and application thereof | 重庆医科大学 | 2024-11-05 | — | — | CN | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| CN-117624166-A | Triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117586277-A | Macrocyclic triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3012259-B1 | FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-06-03 | — | — | EP | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2822559-A1 | IMIDAZO [1, 2 - B]PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | Lexicon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2822956-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| WO-2013134415-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013134219-A1 | IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | TNF 4121/4885DYRK1A 1689/4885DYRK2 1797/4885 |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | TNF 4625/4885DYRK1A 1398/4885DYRK2 1424/4885 |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | TNF 4625/4885DYRK1A 1398/4885DYRK2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.